# A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

> **NCT03999658** · PHASE2 · WITHDRAWN · sponsor: **Sorrento Therapeutics, Inc.**

## Conditions studied

- Peripheral T Cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Biliary Tract Cancer
- Extranodal NK T Cell Lymphoma, Nasal

## Interventions

- **BIOLOGICAL:** STI-3031

## Key facts

- **NCT ID:** NCT03999658
- **Lead sponsor:** Sorrento Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-03
- **Primary completion:** 2024-01
- **Final completion:** 2024-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sorrento Therapeutics filed for chapter 11 bankruptcy.
- **Last updated:** 2023-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03999658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03999658, "A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03999658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*